Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909796 | 1.00 | ACACB (0.45) | ACACBACACA | |
| SCHEMBL29354548 | 1.00 | ACACB (0.45) | ACACBACACA | |
| SCHEMBL30901794 | 1.00 | ACACB (0.45) | ACACBACACA | |
| SCHEMBL18908171 | 0.87 | ACACB (0.44) | ACACBACACA | |
| SCHEMBL14945397 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14945398 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL21816549 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29642175 | 0.86 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL17580347 | 0.86 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL17580298 | 0.86 | ACACB (0.43) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111484504-B | Optical isomer of ACC inhibitor and application thereof | 南京圣和药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-116745299-A | Thienopyrimidine derivatives | 正大天晴药业集团股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4071153-B1 | CRYSTAL FORM OF THIENO[2,3-C]PYRIDAZINE-4(1H)-ONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4071154-B1 | CRYSTAL FORM AS INHIBITOR OF ACC1 AND ACC2, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-114599654-B | ACC inhibitor and application thereof | 南京瑞捷医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116354983-A | Phenyl substituted compound, preparation method and application thereof | 南京汇诚制药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116354982-A | Preparation method of ACC inhibitor | 南京汇诚制药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116354984-A | Preparation method of phenyl substituted ACC inhibitor and intermediate thereof | 南京汇诚制药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| EP-4056574-A1 | ACC INHIBITOR AND USE THEREOF | Nanjing Ruijie Pharma Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| CN-113968872-A | Preparation method of phenyl substituted ACC inhibitor | 南京圣和药业股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113967213-A | Composition containing phenyl substituted ACC inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| WO-2021110138-A1 | CRYSTAL FORM OF THIENO[2,3-C]PYRIDAZINE-4(1H)-ONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 漳州片仔癀药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| CN-112778325-A | ACC inhibitor and application thereof | 南京瑞捷医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-111848678-A | Phosphorus-containing thienopyrimidine derivatives | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111484504-A | Optical isomer of ACC inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-3660023-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| CN-110959007-A | Compounds as ACC inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2020-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.